Merck & Co., Inc (0QAH)
Summary
0QAH Chart
Why Merck (MRK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Merck & Co., Inc. ( MRK ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Caroline Litchfield - Executive VP & CFO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Daina Graybosch - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Merck & Co., Inc (0QAH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Merck & Co., Inc ever had a stock split?
Merck & Co., Inc Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Robert M. Davis CEO | LSE Exchange | US58933Y1055 ISIN |
| US Country | 73,000 Employees | 15 Sep 2025 Last Dividend | 3 Jun 2021 Last Split | 13 Jan 1978 IPO Date |
Overview
Merck & Co., Inc. is a global healthcare leader focused on innovating new solutions to tackle some of the most serious health challenges. Founded in 1891 and headquartered in Rahway, New Jersey, the company operates worldwide, engaging in the discovery, development, manufacturing, and marketing of pharmaceuticals and animal health products. It operates two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is dedicated to developing and offering human health pharmaceutical products across a range of areas including oncology, cardiovascular, and diabetes, among others. The Animal Health segment works on veterinary pharmaceuticals, vaccines, and health management solutions and services. Merck serves a diverse clientele, including drug wholesalers, retailers, hospitals, government agencies, physicians, veterinarians, and pet owners. Notably, the company invests in several strategic collaborations and agreements with other pharmaceutical giants like AstraZeneca PLC and Bayer AG, aiming to enhance its product offerings and harness innovative treatments for multiple diseases.
Products and Services
The products and services offered by Merck & Co., Inc. span a broad spectrum of medical needs in both human and animal health sectors:
- Keytruda: A forefront immunotherapy for treating various types of cancer.
- Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia: A portfolio of pharmaceuticals addressing hospital acute care, neuroscience, virology, cardiovascular, and diabetes.
- Vaccine Products: Including preventive pediatric, adolescent, and adult vaccines with prominent products like Gardasil/Gardasil 9 for HPV, ProQuad, M-M-R II, and Varivax for measles, mumps, rubella, and chickenpox, RotaTeq for rotavirus, Vaxneuvance for pneumococcal infections, Pneumovax 23 for pneumonia, and Vaqta for hepatitis A.
- Animal Health Solutions: Veterinary pharmaceuticals, vaccines, health management solutions and services, along with digitally connected identification, traceability, and monitoring products aimed at veterinarians, distributors, animal producers, farmers, and pet owners.
In the arena of collaborative efforts, Merck has entered into multiple significant agreements to bolster its product pipeline:
- Daiichi Sankyo's deruxtecan ADC candidates: A development and commercialization agreement covering patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for treating multiple solid tumors.
- AstraZeneca's Lynparza and Koselugo: Co-development and co-commercialization for multiple cancer types, enhancing Merck's portfolio in oncology.
- Collaborations across the industry: Partnerships with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well as Moderna, Inc., aiming to explore and bring new treatments and vaccines to market.
Contact Information
